Table 2.

Median baseline and six-week changes in brachial artery flow-mediated dilation on telmisartan therapy.^*

Overall	FMD (%)	Relative change	p-value£
Week 0	2.7 (1.4, 3.9)
Week 6	3.5 (1.6, 6.0)
6-week change	0.7 (−1.3, 1.9)	26%	0.60
On abacavir †
Week 0	2.7 (1.4, 3.4)
Week 6	5.7 (5.3, 6.3)
6-week change	2.3 (−1.2, 4.0)	85%	0.31
On tenofovir
Week 0	2.9 (2.1, 8.4)
Week 6	3.5 (2.3, 3.8)
6-week change	0.8 (−0.3, 1.1)	28%	0.57
On PI ⌘
Week 0	2.7 (1.2, 3.5)
Week 6	3.8 (1.4, 6.3)
6-week change	1.1 (0.4, 4.0)	41%	0.08
Not on PI
Week 0	8.4 (2.1, 10.4)
Week 6	3.3 (1.7, 3.5)
6-week change	−1.2 (−4.9, −0.3)	−14%	0.19
Current smoker #
Week 0	2.1 (1.0, 10.4)
Week 6	1.7 (1.4, 3.3)
6-week change	−0.3 (−7.1, 0.4)	−14%	0.75
Non-smoker
Week 0	2.9 (1.4, 3.9)
Week 6	3.8 (2.3, 6.3)
6-week change	1.0 (−1.2, 2.3)	34%	0.38

^*Values expressed as median (interquartile range).

^£Wilcoxon signed rank value for six-week change.

^†p=0.52 vs. tenofovir

^⌘p=0.02 vs. not on a protease inhibitor

^#p=0.15 vs. non-smoker

FMD: flow-mediated dilation; PI: protease inhibitor